The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | An update on CARTITUDE-2: cilta-cel in patients with multiple myeloma in second line
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, gives an update on the CARTITUDE-2 study (NCT04133636) evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma in the second-line setting. The study did not report increased rates of toxicity when compared to CARTITUDE-1 (NCT03548207). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
